Hotspot mutations occurring in the codon 835 of the FLT3 oncogene have been implicated in the majority of AML and ALL patients [59], and recurrent aberrations such as D816V and V560D found in the KIT oncogene have been associated with patients suffering from AML and gastric cancer, respectively [60,61]. The gene discussed is FLT3; the disease is gastric cancer.